January 10, 2022 | Berlin and Radeberg, Germany
TRIMT GmbH (TRIMT) and Eckert & Ziegler Eurotope GmbH (Eckert & Ziegler) have signed a service agreement to develop a reliable and fast automated synthesis process for TRIMT’s PET tracer Ga-68-Trivehexin using Eckert & Ziegler’s synthesis platforms and equipment. Under the agreement, both companies have also joined forces in the marketing for Trivehexin labelled on Modular-Lab eazy and PharmTracer using Eckert & Ziegler’s proprietary Ga-68 generators.
TRIMT develops diagnostic and therapeutic radiopharmaceuticals. The lead product Ga-68-Trivehexin showed promising preclinical and clinical results in diagnostic positron emission tomography (PET) imaging of various carcinomas.
“We are thrilled to partner with Eckert & Ziegler for the development of a fast and reliable synthesis process for our Ga-68-Trivehexin. This opens up new opportunities for us to add more options for the treatment of patients with life-threatening diseases”, stated Dr. Jakub Simecek, TRIMT’s CEO and co-founder.
“The collaboration with TRIMT confirms our business focus to facilitate and drive innovative new radiopharmaceuticals to become accessible for nuclear medicine institutions. We are glad to contribute our radiopharmaceutical expertise and equipment to the development of this promising PET-tracer and make the process available to users all over the world.”, added Dr. Sven-Peter Heyn, general manager of Eckert & Ziegler Eurotope GmbH.
TRIMT´s technology exploits a cell surface protein, called αvβ6-integrin, which is found, for example, in high density on many tumor cells and represents an indicator for a particularly aggressive growth. The radioligand Ga-68-Trivehexin specifically binds to this protein and marks the respective cells by emitting small amounts of radiation. The positions of tumors within the patient’s body can then be determined by highly sensitive detection external systems, such as PET scanners, facilitating the localization even of small tumors anywhere in the body. The 3D images obtained with Ga-68-Trivehexin PET should help surgeons and oncologists to optimize their treatment, ideally facilitating complete surgical removal, or a better monitoring of the responsivness to a chemotherapy.
TRIMT GmbH was founded in early 2021 in Radeberg. The strategically advantageous position near Dresden (Saxony) was chosen due to the city’s historical importance in radiopharmaceutical sciences. The location offers a cluster of excellent knowhow and collaboration opportunities – ranging from academia (TU Dresden) to established companies which are committed to chemistry and life science research, as well as to pharmaceutical manufacturing and production of radiopharmaceuticals.
TRIMT holds a worldwide exclusive licence for various new radioligands based on technologies from the Technical University of Munich.
Dr. Jakub Simecek, CEO
Carl-Eschebach-Str. 7, 01454 Radeberg, Germany
Tel +49 (0) 3528 487 1940, www.trimt.de
About Eckert & Ziegler Eurotope GmbH
Eurotope GmbH belongs to the Eckert & Ziegler group and represents the Lab Devices business unit of the Medical Segment. The company develops, manufactures and sells systems and accessories for radionuclide labeling and quality control of radiopharmaceuticals. The products are used in research and routine manufacturing of patient doses for cancer diagnosis and therapy in hospitals as well as in industrial manufacturing processes for radioactively labeled compounds and drugs.
As part of the Medical Segment, Eurotope GmbH contributes to provide complete solutions to Eckert & Ziegler´s worldwide customers in the nuclear medicine and pharma industry. The comprehensive product and service portfolio ranges from customized hot cell solutions and in-cell equipment over radionuclides to contract development and GMP-manufacturing services for radiopharmaceuticals through all stages from early clinical to commercial supply.